HUP0203834A2 - Sertéseredetű cirkovírus-2-vel asszociált szívizomgyulladás, abortusz és méhen belüli fertőzés prevenciója - Google Patents

Sertéseredetű cirkovírus-2-vel asszociált szívizomgyulladás, abortusz és méhen belüli fertőzés prevenciója

Info

Publication number
HUP0203834A2
HUP0203834A2 HU0203834A HUP0203834A HUP0203834A2 HU P0203834 A2 HUP0203834 A2 HU P0203834A2 HU 0203834 A HU0203834 A HU 0203834A HU P0203834 A HUP0203834 A HU P0203834A HU P0203834 A2 HUP0203834 A2 HU P0203834A2
Authority
HU
Hungary
Prior art keywords
abortion
prevention
myocarditis
intrauterine infection
porcine circovirus
Prior art date
Application number
HU0203834A
Other languages
English (en)
Inventor
Gordon Moore Allan
Jean-Christophe Francis Audonnet
Gilles Emile Chappuis
Catherine E. Charreyre
Edward Clark
John Albert Ellis
Deborah Haines
John Harding
Lori Hassard
George Steven Krakowka
Francis Mcneilly
Brian Meehan
Original Assignee
Merial
The Queen's University Of Belfast
University Of Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26848763&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0203834(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merial, The Queen's University Of Belfast, University Of Saskatchewan filed Critical Merial
Publication of HUP0203834A2 publication Critical patent/HUP0203834A2/hu
Publication of HUP0203834A3 publication Critical patent/HUP0203834A3/hu
Publication of HU229195B1 publication Critical patent/HU229195B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A találmány tárgyát eljárások és készítmények képezik PCV-2 általokozott miokardítisz (szívizomgyulladás), abortusz és méhen belüli(intrauterin) fertőzés, valamint elválasztás utáni, multiszisztémássorvadási szindróma (<postweaning multisystemic wasting syndrome<)patológiás következményeinek prevenciójára és kezelésére, továbbáeljárások a találmány szerinti készítmények előállítására, ésreagenskészletek a találmány szerinti készítmények előállítására és atalálmány szerinti eljárások végrehajtására. Ó
HU0203834A 1999-08-31 2000-08-28 Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2 HU229195B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15156499P 1999-08-31 1999-08-31
US09/583,350 US6517843B1 (en) 1999-08-31 2000-05-31 Reduction of porcine circovirus-2 viral load with inactivated PCV-2
PCT/EP2000/008781 WO2001016330A2 (en) 1999-08-31 2000-08-28 Prevention of affections associated with porcine circovirus-2

Publications (3)

Publication Number Publication Date
HUP0203834A2 true HUP0203834A2 (hu) 2003-03-28
HUP0203834A3 HUP0203834A3 (en) 2004-07-28
HU229195B1 HU229195B1 (en) 2013-09-30

Family

ID=26848763

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203834A HU229195B1 (en) 1999-08-31 2000-08-28 Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2

Country Status (16)

Country Link
US (1) US6517843B1 (hu)
EP (1) EP1246920B1 (hu)
JP (1) JP2003513617A (hu)
KR (1) KR20020068325A (hu)
CN (2) CN1409765A (hu)
AT (1) ATE527361T1 (hu)
AU (2) AU782418B2 (hu)
BR (2) BRPI0014155B1 (hu)
CA (1) CA2383367C (hu)
DK (1) DK1246920T3 (hu)
ES (1) ES2376817T3 (hu)
HU (1) HU229195B1 (hu)
MX (1) MXPA02002208A (hu)
PL (1) PL205130B1 (hu)
PT (1) PT1246920E (hu)
WO (1) WO2001016330A2 (hu)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39494E1 (en) * 1992-02-27 2007-02-27 Intervet Inc. Inactivated mycoplasma hyopneumoniae and uses therefor
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US20040062775A1 (en) * 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US6497883B1 (en) * 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
JP4024041B2 (ja) * 1999-08-20 2007-12-19 旭化成メディカル株式会社 生理活性物質溶液用濾過膜
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
UA82647C2 (uk) * 2001-03-27 2008-05-12 Юниверсити Оф Саскачеван Спосіб культивування цирковірусу ссавця
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
WO2005007223A2 (en) * 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
EP1689858B1 (en) 2003-11-13 2013-05-15 University Of Georgia Research Foundation, Inc. Methods of characterizing infectious bursal disease virus
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
CN102660578B (zh) 2004-12-30 2016-12-14 勃林格殷格翰动物保健有限公司 Pcv2免疫原性组合物和产生这种组合物的方法
UA95602C2 (ru) * 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7566562B2 (en) 2005-02-03 2009-07-28 Universiteit Gent Culturing circular ssDNA viruses for the production of vaccines
US7300785B2 (en) 2005-02-03 2007-11-27 Universiteit Ghent Culturing circular ssDNA viruses for the production of vaccines
UA95458C2 (ru) * 2005-09-09 2011-08-10 Интервет Интернешонал Б.В. Вакцина против pcv-2 у mda-положительных поросят
DK3127551T3 (da) * 2005-12-29 2020-10-12 Boehringer Ingelheim Animal Health Usa Inc Pcv2-immunogen-sammensætning til at mindske kliniske symptomer i grise
EP1968630B1 (en) * 2005-12-29 2018-01-24 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US20100129397A1 (en) * 2006-12-11 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
PT2481420T (pt) * 2006-12-15 2019-05-31 Boehringer Ingelheim Animal Health Usa Inc Vacina para porcos anti-pcv2 de dose única
EP1941903A1 (en) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) * 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
JP2011508595A (ja) * 2007-12-31 2011-03-17 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド 外来性アミノ酸の挿入を含むｐｃｖ２ｏｒｆ２ウイルス様粒子
US20090317423A1 (en) * 2008-01-23 2009-12-24 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
WO2009103037A1 (en) * 2008-02-15 2009-08-20 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
TWI627281B (zh) * 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
KR20110090711A (ko) * 2010-02-04 2011-08-10 녹십자수의약품(주) 신규한 돼지 써코바이러스 타입 2 및 그의 용도
KR101484469B1 (ko) * 2010-10-26 2015-01-21 주식회사 중앙백신연구소 돼지 써코바이러스 관련 질환을 예방하기 위한 ｐｃｖ-2의 전체 바이러스를 포함하는 혼합백신
TWI508974B (zh) 2010-12-22 2015-11-21 Sbc Virbac Ltd 豬第二型環狀病毒(Porcine Circovirus Type 2)、含彼之免疫組合物、檢測套組及其應用
JP6821429B2 (ja) 2013-09-25 2021-01-27 ゾエティス・サービシーズ・エルエルシー Ｐｃｖ２ｂ分岐ワクチン組成物及び使用方法
US9505808B2 (en) 2013-10-02 2016-11-29 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
WO2016183423A1 (en) 2015-05-14 2016-11-17 Merial Inc. Method for porcine circovirus production and pcv2 vaccines
BR112023001324A2 (pt) 2020-07-24 2023-02-14 Boehringer Ingelheim Animal Health Usa Inc Combinação de vacina de suíno
CN112655566B (zh) * 2020-12-18 2022-07-29 杭州惠通检测有限公司 一种在非洲猪瘟防控中应用的多层防御体系

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP0386185A1 (fr) 1988-07-29 1990-09-12 IntraCel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
DK0465529T3 (da) 1989-03-21 1998-10-05 Vical Inc Ekspression af exogene polynukleotidsekvenser i et hvirveldyr
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
JPH04506662A (ja) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
JPH04183026A (ja) 1990-11-16 1992-06-30 Matsushita Electric Ind Co Ltd 表示付き選択呼出受信装置
WO1992015672A1 (en) 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
US5869312A (en) 1992-01-13 1999-02-09 Syntro Corporation Recombinant swinepox virus
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
US6033904A (en) 1992-01-13 2000-03-07 Syntro Corporation Recombinant swinepox virus
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
DE69536091D1 (de) 1994-01-27 2010-09-09 Univ Massachusetts Medical Immunisierung durch Impfung von DNS Transkriptionseinheit
EP0758397B1 (en) 1994-04-29 2005-06-22 Baxter Healthcare S.A. Recombinant poxviruses with foreign polynucleotides in essential regions
JPH11502222A (ja) 1995-03-23 1999-02-23 キャンタブ ファーマシューティカルズ リサーチ リミティド 遺伝子供給用ベクター
WO1998000166A1 (en) 1996-07-03 1998-01-08 Merial, Inc. Recombinant canine adenovirus (cav) containing exogenous dna
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
UA78180C2 (uk) * 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
FR2781159B1 (fr) 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
CA2313806A1 (en) 1997-12-11 1999-06-17 University Of Saskatchewan Postweaning multisystemic wasting syndrome virus from pigs
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US6497883B1 (en) * 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US8235898B2 (en) 2004-08-27 2012-08-07 University Of Washington Through Its Center For Commercialization Ultrasonic direct strain estimation using temporal and spatial correlation

Also Published As

Publication number Publication date
PL353068A1 (en) 2003-10-06
ES2376817T3 (es) 2012-03-20
AU2005220241A1 (en) 2005-12-01
CA2383367A1 (en) 2001-03-08
CN102416173A (zh) 2012-04-18
EP1246920B1 (en) 2011-10-05
AU7285500A (en) 2001-03-26
ATE527361T1 (de) 2011-10-15
CN1409765A (zh) 2003-04-09
WO2001016330A2 (en) 2001-03-08
KR20020068325A (ko) 2002-08-27
PT1246920E (pt) 2011-10-24
WO2001016330A3 (en) 2002-08-08
EP1246920A2 (en) 2002-10-09
HU229195B1 (en) 2013-09-30
BRPI0014155B1 (pt) 2017-09-12
PL205130B1 (pl) 2010-03-31
JP2003513617A (ja) 2003-04-15
DK1246920T3 (da) 2011-10-31
AU782418B2 (en) 2005-07-28
BR0014155A (pt) 2002-05-07
CA2383367C (en) 2015-04-07
AU2005220241B2 (en) 2009-12-10
CN102416173B (zh) 2016-08-03
US6517843B1 (en) 2003-02-11
MXPA02002208A (es) 2002-11-07
HUP0203834A3 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
HUP0203834A2 (hu) Sertéseredetű cirkovírus-2-vel asszociált szívizomgyulladás, abortusz és méhen belüli fertőzés prevenciója
HK1085140A1 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
DE60019473D1 (de) (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
HRP20060251A2 (en) Substituted oxasolidinones and their use
HUP0203056A1 (hu) Vakcinakészítmény
ME00513B (me) Azabicikloalkani kao modulatori ccr5
MY127290A (en) New use of flibanserin
NO20061291L (no) Ny formulering
HUP0200714A2 (hu) Gyógyhatású vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE491436T1 (de) Zusammensetzungen gegen infektionen zur behandlung erkrankten gewebes wie z.b. fieberbläschen
PL356846A1 (en) Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
NO20053348L (no) Farmasoytisk sammensetning for behandling av virusangrep.
CA3155883A1 (en) BUCCO-DENTAL CARE COMPOSITIONS BASED ON BETA ACID OF HOPS AND AMINO ACID
ATE299854T1 (de) Chinonverbindungen zur behandlung von krankheiten
EE200400005A (et) Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine
AU2020256283A8 (en) Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof
BR0203517A (pt) Composição farmacêutica estéril aquosa, e, método para preparar uma composição farmacêutica estéril aquosa
PL350917A1 (en) C16 unsaturated fp-selective prostaglandins analogs
HUP0401042A2 (hu) Primer álmatlanság kezelésére alkalmas gyógyszerkészítmények
DE60311351D1 (de) Verwendung von Zeoliten zur Herstellung oraler Zubereitungen zur Behandlung von Vergiftung
EP1247533A3 (en) Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
DE60108402D1 (de) Verwendung einer pollenextrakt-haltigen verbindung zur behandlung erkrankungsbedingter gewichtszunahme
EP1370697A4 (en) PEROXYREDOXIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-1 INFECTIONS AND METHODS OF USE
DE60305018D1 (de) Citalopram zur behandlung von bluthochdruck